Key facts for J9260
- Billing unit
- 50 MG
- Inj methotrexate sodium 50mg
- ASP payment limit
- $2.909
- October 2026; -1.1% vs July 2026
- Practitioner MUE
- 400
- MAI 3
- OPPS status
- SI N
- NCCI exposure
- no PTP pairs
- Coverage articles
- 1
- 4 states
TL;DR
HCPCS J9260 is the Level II code for Injection, methotrexate sodium, 50 mg, billed per 50 MG. The Medicare Part B ASP payment limit for October 2026 is $2.909 per billing unit, down 1.1% from July 2026. The practitioner MUE allows up to 400 units per date of service (MAI 3), so a full 400-unit day is $1,163.60 at the current limit. Under OPPS it carries status indicator N. J9260 is billed in units of 50 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names methotrexate: J8612 (Xatmep from Azurity Pharmaceuticals, Inc.; oral route; billed per 2.5 mg); J8611 (Jylamvo from Shorla Oncology Inc.; oral route; billed per 2.5 mg). The ASP crosswalk maps 18 NDCs to it, sold as Methotrexate Sodium by Hikma Pharmaceuticals USA Inc., Teva Parenteral Medicines, Inc., ACCORD HEALTHCARE INC. 1 Medicare coverage article lists the code across 4 states, including A55639.
Medicare Part B payment limit (ASP)
CMS sets the Part B payment limit for J9260 at $2.909 per 50 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $2.941 in July 2026. Beneficiary coinsurance is 20%.
| Quarter | Payment limit | Per | Coinsurance |
|---|---|---|---|
| October 2026 | $2.909 | 50 MG | 20% |
| July 2026 | $2.941 | 50 MG | — |
NDC to HCPCS billing-unit conversion
The October 2026 ASP crosswalk maps 18 NDCs from 6 labelers to J9260. Report the NDC in the claim's drug segment and bill the number of J9260 units that equals the quantity administered divided by 50 MG; the last column gives units per full package.
| NDC | Drug name | Labeler | Package size | Billing units / package |
|---|---|---|---|---|
| 00143-9367-01 | Methotrexate Sodium | Hikma Pharmaceuticals USA Inc. | 1 × 1 | 20 |
| 00143-9519-10 | Methotrexate Sodium | Hikma Pharmaceuticals USA Inc. | 2 × 10 | 10 |
| 00143-9830-01 | Methotrexate Sodium | Hikma Pharmaceuticals USA Inc. | 1 × 1 | 20 |
| 00703-3671-01 | Methotrexate Sodium | Teva Parenteral Medicines, Inc. | 2 × 1 | 1 |
| 00703-3675-01 | Methotrexate Sodium | Teva Parenteral Medicines, Inc. | 10 × 1 | 5 |
| 00703-3678-01 | Methotrexate Sodium | Teva Parenteral Medicines, Inc. | 40 × 1 | 20 |
| 00703-3678-81 | Methotrexate Sodium | Teva Parenteral Medicines, Inc. | 40 × 1 | 20 |
| 16729-0277-03 | Methotrexate Sodium | ACCORD HEALTHCARE INC | 10 × 1 | 5 |
| 16729-0277-30 | Methotrexate Sodium | Accord Healthcare Inc | 2 × 1 | 1 |
| 16729-0277-35 | Methotrexate Sodium | Accord Healthcare Inc | 40 × 1 | 20 |
| 61703-0124-40 | Methotrexate Sodium | Pfizer Inc | 40 × 1 | 20 |
| 61703-0161-05 | Methotrexate Sodium | Pfizer Inc | 2 × 5 | 5 |
| 61703-0350-10 | Methotrexate Sodium | Pfizer Inc | 2 × 5 | 5 |
| 61703-0350-38 | Methotrexate Sodium | Pfizer Inc | 2 × 5 | 5 |
| 61703-0408-25 | Methotrexate Sodium | Pfizer Inc | 40 × 1 | 20 |
| 61703-0408-41 | Methotrexate Sodium | Pfizer Inc | 40 × 1 | 20 |
| 63323-0122-50 | Methotrexate Sodium | FreseniUS Kabi USA, LLC | 1 × 1 | 20 |
| 63323-0123-10 | Methotrexate Sodium | FreseniUS Kabi USA, LLC | 10 × 1 | 5 |
Medically Unlikely Edits (MUE)
CMS publishes 3 MUE values for J9260. For practitioners the limit is 400 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.
| Setting | MUE (units/DOS) | MAI | CMS rationale |
|---|---|---|---|
| Practitioner services | 400 | 3 Date of Service Edit: Clinical | Prescribing Information |
| Facility outpatient hospital | 400 | 3 Date of Service Edit: Clinical | Prescribing Information |
| DME supplier | 400 | 3 Date of Service Edit: Clinical | Prescribing Information |
MUE for J9260 in every setting opens the lookup with this code filled in, next to any other code on the same claim.
NCCI edits and add-on relationships
No active practitioner PTP pair lists J9260 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.
The counts above are exposure, not answers for a specific claim. Check J9260 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.
J9260 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.
Medicare coverage articles
1 current Medicare Administrative Contractor article lists J9260 in their HCPCS tables, covering 4 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.
| Article | Title | Contractor(s) | States | Related LCD |
|---|---|---|---|---|
| A55639 | Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions | Wisconsin Physicians Service Insurance Corporation | IA KS MO NE | L37205 |
Diagnoses Medicare contractors cover for J9260
One billing and coding article attaches a covered diagnosis list to J9260: 299 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).
| ICD-10-CM | Description (FY2027) | Articles covering |
|---|---|---|
| J84.111 | Idiopathic interstitial pneumonia, not otherwise specified | 1 of 1 |
| J84.112 | Idiopathic pulmonary fibrosis | 1 of 1 |
| J84.113 | Idiopathic non-specific interstitial pneumonitis | 1 of 1 |
| J84.114 | Acute interstitial pneumonitis | 1 of 1 |
| J84.115 | Respiratory bronchiolitis interstitial lung disease | 1 of 1 |
| J84.116 | Cryptogenic organizing pneumonia | 1 of 1 |
| J84.117 | Desquamative interstitial pneumonia | 1 of 1 |
| J84.170 | Interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere | 1 of 1 |
| J84.178 | Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere | 1 of 1 |
| L12.0 | Bullous pemphigoid | 1 of 1 |
| L12.8 | Other pemphigoid | 1 of 1 |
| L40.0 | Psoriasis vulgaris | 1 of 1 |
| L40.1 | Generalized pustular psoriasis | 1 of 1 |
| L40.2 | Acrodermatitis continua | 1 of 1 |
| L40.3 | Pustulosis palmaris et plantaris | 1 of 1 |
Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J9260 are counted here: a group whose instructions name J9260, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.
| Article | Contractor | Groups that apply | Covered codes for J9260 | Full list |
|---|---|---|---|---|
| A55639 | Wisconsin Physicians Service Insurance Corporation | group 2 applies to J9260 | 299 | On LCD L37205 |
Local coverage policies that list J9260
1 active Local Coverage Determination lists J9260 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.
- L37205 Chemotherapy Drugs and their Adjuncts · Wisconsin Physicians Service Insurance Corporation
Hospital outpatient (OPPS) status
In the October 2026 OPPS Addendum B, J9260 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.
Ambulatory surgical center (ASC) payment
In the October 2026 ASC Addendum BB (covered ancillary services), J9260 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.
Common denials for J9260 and how to prevent them
For teams evaluating QuickIntell software
Evaluate a coding workflow for J9260
Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
In QuickIntell research
- J codes by drug name: Every code for the same drug, generic or brand, in one A-Z index.
Frequently asked questions — HCPCS J9260
What does HCPCS code J9260 describe?
J9260 is defined by CMS as "Injection, methotrexate sodium, 50 mg". Each billing unit represents 50 MG, so the units reported on the claim must equal the dose administered divided by that unit.
Is J9260 a CPT code?
No. J9260 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as methotrexate sodium; CPT codes are five-character codes maintained by the AMA. On a Part B claim J9260 reports the drug itself in 50 mg units, and the administration is billed on its own line.
What is the Medicare reimbursement for J9260 in October 2026?
The ASP-based payment limit is $2.909 per 50 MG, with 20% beneficiary coinsurance. The July 2026 limit was $2.941. Commercial payers use their own fee schedules.
How many units of J9260 can be billed per day?
The practitioner Medically Unlikely Edit is 400 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.
Which NDCs map to J9260?
The October 2026 ASP crosswalk lists 18 NDCs from 6 labelers: Methotrexate Sodium (Hikma Pharmaceuticals USA Inc.); Methotrexate Sodium (Teva Parenteral Medicines, Inc.); Methotrexate Sodium (ACCORD HEALTHCARE INC); Methotrexate Sodium (Accord Healthcare Inc). For example NDC 00143-9367-01 (package size 1) equals 20 billing units of J9260.
Does J9260 have NCCI bundling edits?
No active practitioner PTP pairs list J9260 as a column-1 or column-2 code in the v323r0 release.
J9260 vs J8612: what is the difference?
Both are HCPCS Level II codes whose descriptor names methotrexate. What sets J8612 apart: Xatmep from Azurity Pharmaceuticals, Inc.; oral route; billed per 2.5 mg. J9260 is billed per 50 mg, limit $2.909, MUE 400; J8612 is billed per 2.5 mg, limit $22.855. Report the code whose descriptor matches the product and setting in the record.
J9260 vs J8611: what is the difference?
Both are HCPCS Level II codes whose descriptor names methotrexate. What sets J8611 apart: Jylamvo from Shorla Oncology Inc.; oral route; billed per 2.5 mg. J9260 is billed per 50 mg, limit $2.909, MUE 400; J8611 is billed per 2.5 mg, limit $18.264. Report the code whose descriptor matches the product and setting in the record.
Which Medicare coverage articles mention J9260?
1 current Billing and Coding Article in the Medicare Coverage Database lists J9260, covering 4 states: A55639 (Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions).
What diagnosis codes support J9260?
One Medicare billing and coding article lists 299 covered ICD-10-CM codes for J9260, for example J84.111 (Idiopathic interstitial pneumonia, not otherwise specified); J84.112 (Idiopathic pulmonary fibrosis); J84.113 (Idiopathic non-specific interstitial pneumonitis); J84.114 (Acute interstitial pneumonitis); J84.115 (Respiratory bronchiolitis interstitial lung disease). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- HCPCS Level II alpha-numeric file, October 2026Version October 2026 · effective 2026-10-01 · file HCPC2026_OCT_ANWEB_09232026.txtSHA-256 c25240c63108756d…
- Medicare Part B Drug Payment Limit File, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 Medicare Part B Payment Limit File 091626.csvSHA-256 508fba376a29e099…
- Medicare Part B Drug Payment Limit File, July 2026Version July 2026 · effective 2026-07-01 · file section 508 version of July 2026 Medicare Part B Payment Limit File updated 082026.csvSHA-256 13bb5b644b92b574…
- ASP NDC-HCPCS Crosswalk, October 2026Version October 2026 · effective 2026-10-01 · file section 508 version of October 2026 ASP NDC-HCPCS Crosswalk 091126.csvSHA-256 5cb78f0c2ee786ba…
- NCCI MUE table, practitioner services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_PractitionerServices_Eff_10-01-2026.csvSHA-256 ef038efaf902b7bd…
- NCCI MUE table, facility services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_OutpatientHospitalServices_Eff_10-01-2026.csvSHA-256 3af9f4e99cc587e2…
- NCCI MUE table, dme services, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file MCR_MUE_DMESupplierServices_Eff_10-01-2026.csvSHA-256 6fa4fbba852f7b74…
- NCCI PTP edits, practitioner, v323r0 (four files)Version v323r0 (2026 Q4) · effective 2026-10-01 · file ccipra-v323r0-f1.TXTSHA-256 7793c0b6686c1e22…
- NCCI Add-On Code edits, effective 2026-10-01Version 2026 Q4 · effective 2026-10-01 · file AOC_V2026Q4-F-MCR.xlsxSHA-256 eabb519623134549…
- OPPS Addendum B, October 2026Version October 2026 · effective 2026-10-01 · file 508-compliant-version-2026_October_Web_Addendum_B.09.28.26.csvSHA-256 6ad7393a318bf1b9…
- ASC Addendum BB (covered ancillary services), October 2026Version October 2026 · effective 2026-10-01 · file Oct 2026 ASC BB.txtSHA-256 63cdd7c72aba7a25…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.